risperidone has been researched along with Acquired Metabolic Diseases, Brain in 1 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with risperidone was correlated with resolution of her psychosis and improvement in neuropsychiatric symptoms." | 1.34 | Hashimoto encephalopathy responding to risperidone. ( Bismilla, Z; Donner, E; Sell, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bismilla, Z | 1 |
| Sell, E | 1 |
| Donner, E | 1 |
1 other study available for risperidone and Acquired Metabolic Diseases, Brain
| Article | Year |
|---|---|
Hashimoto encephalopathy responding to risperidone.
Topics: Antipsychotic Agents; Autoantibodies; Brain Diseases, Metabolic; Child; Female; Hashimoto Disease; H | 2007 |